DETECTION OF PROSTATE CANCER WITH
            <sup>11</sup>
            C-METHIONINE POSITRON EMISSION TOMOGRAPHY

Tóth, Gabriella; Lengyel, Zsolt; Balkay, László; Salah, Morshed Ali; Trón, Lajos; Tóth, Csaba

doi:10.1097/01.ju.0000148326.71981.44

Cited by 67 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Cmethionine is an amino acid radiotracer that, in limited studies, demonstrated a sensitivity of 72% in the detection of metastatic prostate cancer ( 44 ) and an overall detection rate of 46.7% for primary carcinoma ( 51 ).…”

mentioning

confidence: 99%

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Schuster

Savir-Baruch²,

Nieh³

et al. 2011

Radiology

139

130

View full text Add to dashboard Cite

Purpose:To compare the diagnostic performance of the synthetic amino acid analog radiotracer anti -1-amino-3-fl uorine 18-fl uorocyclobutane-1-carboxylic acid ( anti -3-18 F-FACBC) with that of indium 111 ( 111 In)-capromab pendetide in the detection of recurrent prostate carcinoma. Materials andMethods:This prospective study was approved by the institutional review board and complied with HIPAA guidelines. Written informed consent was obtained. In-capromab pendetide single photon emission computed tomography (SPECT)/CT were performed within 6 weeks of each other. Studies were evaluated by two experienced interpreters for abnormal uptake suspicious for recurrent disease in the prostate bed and extraprostatic locations. The reference standard was a combination of tissue correlation , imaging, laboratory, and clinical data. Diagnostic performance measures were calculated and tests of the statistical signifi cance of differences determined by using the McNemar x 2 test as well as approximate tests based on the difference between two proportions. Results:For disease detection in the prostate bed, anti -3-18 F-FACBC had a sensitivity of 89 % (32 of 36 patients; 95% confi dence interval [CI]: 74%, 97%), specifi city of 67% (eight of 12 patients; 95% CI: 35%, 90%), and accuracy of 83% (40 of 48 patients; 95% CI: 70%, 93%).111 In-capromab pendetide had a sensitivity of 69% (25 of 36 patients; 95% CI: 52%, 84%), specifi city of 58% (seven of 12 patients; 95% CI: 28%, 85%), and accuracy of 67% (32 of 48 patients; 95% CI: 52%, 80%). In the detection of extraprostatic recurrence, anti -3-18 F-FACBC had a sensitivity of 100% (10 of 10 patients; 95% CI: 69%, 100%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 100% (17 of 17 patients; 95% CI: 80%, 100%).111 In-capromab pendetide had a sensitivity of 10% (one of 10 patients; 95% CI: 0%, 45%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 47% (eight of 17 patients; 95% CI: 23%, 72%). Conclusion:anti -3-18 F-FACBC PET/CT was more sensitive than 111 Incapromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease.

show abstract

mentioning

confidence: 99%

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Schuster

Savir-Baruch²,

Nieh³

et al. 2011

Radiology

139

130

View full text Add to dashboard Cite

show abstract

“…Suspect 11 C-MET uptake was noted in 75% of subjects (15/20), 46.7% of whom (7/15) had prostate cancer confirmed by 11 C-MET-guided biopsy (28). However, the fact that 8 subjects with focal 11 C-MET uptake and negative guided biopsies had either benign prostatic hyperplasia (6/8) or chronic prostatitis (2/8) demonstrates a limitation in the evaluation of primary prostate cancer.…”

Section: Investigations With Radiolabeled Naturally Occurring Amino Amentioning

confidence: 90%

“…Radiolabeled naturally occurring amino acids, such as L-11 Cmethionine ( 11 C-MET) and L-1-11 C-5-hydroxytryptophan, were the first radiotracers used in amino acid-based molecular imaging of prostate cancer (26)(27)(28)(29).…”

Section: Investigations With Radiolabeled Naturally Occurring Amino Amentioning

confidence: 99%

Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs

2016

View full text Add to dashboard Cite

Conventional imaging of prostate cancer has limitations related to the frequently indolent biology of the disease. PET is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Radiotracers that are in use or under investigation for targeting salient features of prostate cancer include those directed to glucose, choline, acetate, prostate-specific membrane antigen, bombesin, and amino acids. The tumor imaging features of this last class of radiotracers mirror the upregulation of transmembrane amino acid transport that is necessary in carcinomas because of increased amino acid use for energy requirements and protein synthesis. Natural and synthetic amino acids radiolabeled for PET imaging have been investigated in prostate cancer patients. Early work with naturally occurring amino acid-derived radiotracers, such as L-11 C-methionine and L-1-11 C-5-hydroxytryptophan, demonstrated promising results, including greater sensitivity than 18 F-FDG for intraprostatic and extraprostatic cancer detection. However, limitations with naturally occurring amino acid-derived compounds, including metabolism of the radiotracer itself, led to the development of synthetic amino acid radiotracers, which are not metabolized and therefore more accurately reflect transmembrane amino acid transport. Of the synthetic amino acid-derived PET radiotracers, anti-1-amino-3-18 F-fluorocyclobutane-1-carboxylic acid ( 18 F-FACBC or 18 F-fluciclovine) has undergone the most promising translation to human use, including the availability of simplified radiosynthesis. Several studies have indicated advantageous biodistribution in the abdomen and pelvis with little renal excretion and bladder activity-characteristics beneficial for prostate cancer imaging. Studies have demonstrated improved lesion detection and diagnostic performance of 18 F-fluciclovine in comparison with conventional imaging, especially for recurrent prostate cancer, although issues with nonspecific uptake limit the potential role of 18 F-fluciclovine in the diagnosis of primary prostate cancer. Although work is ongoing, recently published intrapatient comparisons of 18 F-fluciclovine with 11 C-choline reported higher overall diagnostic performance of the former, especially for the detection of disease relapse. This review is aimed at providing a detailed overview of amino acid-derived PET compounds that have been studied for use in prostate cancer imaging.

show abstract

“…11 C-choline and 18 F-fluorocholine are widely used PET radiotracers for prostate cancer imaging (9,20), but also 11 C-methionine and 11 C-acetate PET have been successfully tested for this indication (32,33). 11 C-choline is known to be rapidly transported into human cancers, including prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Evaluation of ¹¹C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer

et al. 2017

View full text Add to dashboard Cite

DETECTION OF PROSTATE CANCER WITH ¹¹ C-METHIONINE POSITRON EMISSION TOMOGRAPHY

Abstract: MET PET of the prostate with short dynamic scanning and multicore biopsy is a useful method to ensure a high detection rate of prostate cancer in patients with increased PSA and repeat negative biopsies.

Cited by 67 publications

References 12 publications

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs

Preclinical Evaluation of ¹¹C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer

Contact Info

Product

Resources

About

DETECTION OF PROSTATE CANCER WITH 11 C-METHIONINE POSITRON EMISSION TOMOGRAPHY

Abstract: MET PET of the prostate with short dynamic scanning and multicore biopsy is a useful method to ensure a high detection rate of prostate cancer in patients with increased PSA and repeat negative biopsies.

Cited by 67 publications

References 12 publications

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT

Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs

Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer

Contact Info

Product

Resources

About

DETECTION OF PROSTATE CANCER WITH ¹¹ C-METHIONINE POSITRON EMISSION TOMOGRAPHY

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Preclinical Evaluation of ¹¹C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer